Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

@article{Israel2004PhaseIT,
  title={Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)},
  author={Valerie K. Israel and Scott T. Tagawa and Terry Snyder and Susan Jeffers and D. Vijaya Raghavan},
  journal={Investigational New Drugs},
  year={2004},
  volume={22},
  pages={291-297}
}
Introduction: The poor prognosis of non small cell lung cancer (NSCLC), as well as the significant toxicity from many conventional cytotoxic regimens warrants the investigation of combinations of new active agents for treatment. This is a phase I–II (dose-finding, efficacy, and toxicity) study of docetaxel + gemcitabine in patients with stage IIIB-IV NSCLC… CONTINUE READING